DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the INFINIUM PHARMACHEM LTD (INFINIUM) share price today?

INFINIUM PHARMACHEM LTD (INFINIUM) is trading at ₹209.5 on the NSE, up 1.67% on the day. Source: DocStoX.

What is the PE ratio of INFINIUM PHARMACHEM LTD?

INFINIUM PHARMACHEM LTD has a price-to-earnings (PE) ratio of 26.9 in the Healthcare sector.

What is the market capitalisation of INFINIUM PHARMACHEM LTD?

INFINIUM PHARMACHEM LTD has a market capitalisation of approximately ₹0 crore.

INFINIUM PHARMACHEM LTD

INFINIUM·NSE·Healthcare

₹209.50▲ +3.45 (+1.67%)

Healthcare · Pharmaceuticals

A steady, established business

52W₹189

₹29419%

Open

₹209.50

High

₹209.50

Low

₹209.50

Prev Close

₹206.05

Volume

1.0K

VWAP

₹209.50

Snapshot

Key fundamentals

Market Cap

₹0 Cr

P/E Ratio

26.86Fair

P/B Ratio

2.73

EPS

₹7.80

Book Value

₹77.70

ROE

10.50%Average

ROCE

13.00%Decent

Dividend Yield

0.00%

Debt / Equity

0.00Low

Face Value

₹10.00

52W High

₹294.00

52W Low

₹189.40

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹86

▼ 59.1%downside

Trading at ₹210 — 59% above our estimate

BearFair valueBull

₹73₹86₹117

/100

Business quality — Watch the fundamentals

Growth 61Profitability 29Efficiency 13Valuation 79

Plain English

Our view

A steady, established business
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 2/9)

Strengths

Virtually debt-free balance sheet
Revenue compounding 19% over 3 years
Promoters hold a controlling stake

Risks

Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

11% ROE fading to 12% over ~3 yrs, on ₹78 book

₹77

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹117

Analyst target

No analyst coverage

—

Blended fair value₹86

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Revenue compounding 19% over 3 years
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

26.9Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

10.5%Average

Above 15% is considered healthy for Indian equities

ROCE

13.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.00Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

—

P/B

2.73

EPS

₹7.80

Div Yield

—

What changed

Recent changes

Domestic institutions+0.2% stake last quarter
Promoters+5.00% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 26.9×

Growth

Strong

+19% rev CAGR

Profitability

Modest

10.5% ROE

Financial health

Rock solid

D/E 0.00

Momentum

N/A

No technicals

Today

Trading activity

Delivery %100.0%

Turnover₹2.10L Cr

Trades2

VWAP₹209.50

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+18.6%

+21.8%

10Y

—

Profit

+11.9%

+36.1%

10Y

—

EPS

-5.7%

-10.5%

10Y

—

Profile

Pros

Company has reduced debt.
Company is almost debt free.
Promoter holding has increased by 5.00% over last quarter.

Watch-outs

Cons

Though the company is reporting repeated profits, it is not paying out dividend
Company has a low return on equity of 14.0% over last 3 years.
Promoter holding has decreased over last 3 years: -35.1%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Promoters raised their stake by 5.00 pts; domestic institutions added 0.19 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

65%

Promoter

Promoters

64.9%+5.00

Public

34.9%-5.20

FII / FPI

0.0%0.00

DII

0.2%+0.19

Total shareholders

1,061+9 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter64.91%

DII0.21%

Public34.87%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates[1]